ORTHOKIN - new approachment in molecular therapy of musculosceletal system

1. ORTHOKIN- new approachment in molecular therapy of musculosceletal system Dr.med. Dr.sci. Milan Marijan Pocrnja

2. Definition and purpose • new discipline on the base of molecular research • combine actual classical medical therapy with new methods from the science of the molecular biology and cell phyisiology • most important changes in the cell proteins structure and genetic informations • after exploration of human genoma with DNA analysis ,proteom analysis and vector analysis (Gentransfer-vehikel) the door for the next generation of therapy is opened PURPOSE Explain and threat the patologic changes on the cell level

3. current therapy • Autologic proteins ( Orthokin®) • Recombined proteins • Gen therapy: • Investigation of structure and way of function of gens and proteins • Analyse of therapeutic molecules • Transfer of gens

4. Keywords • Citokyns • Chondral demage • IL-1β • IL-1Ra - Interleukin1 receptor antagonist

5. Citokyns • cell-cell imunologic system transmitters • heterogenic nature, from different cell populations • could be free or on the cell • could act as autocrin, paracrin or endocrin • have a central role in the cell-cell comunication • samples: autokins, limfokins, chemokins, interferon, interleukins and different growth factors

6. Acting in the cell

7. Cataboliccitokins z.B. IL-1, TNFα, IL-17, IL-18 Anabolic citokins Growth factors,IGF-1, TGF-βs, BMPs, Cell Anti-catabolic cytokins z.B. IL-1RA, IL-4, IL-10, IL-13 Modulators z.B. IL-6, IL-11 Difference in the functionality CITOKINS

8. Demaged knee

9. Example: Interleukin 1 Interleukin 1 (IL-1),protein of imunologic system wich has the most important role in the arthrosis , neurologic pain and cartilage distruction Chondral destruction Moving dissfunction Iritation of nerves Inflammations

10. Chondral destruction in arthrosis- to lesss production of IL1-Ra

11. Orthokin®therapy systemmake the fasterproduction of IL-1Ra Orthokin IL-1/IL-1Ra 1 / >140 • Normal synovial fluid • IL-1/IL-1Ra • 1 /1 - Path.synovial fluid IL-1/IL-1Ra >10 / 1 • IL-1Ra block the receptor and the bad effects of IL-1 • making the natural balance in the imunologic system

12. Placebo IL-1Ra Placebo IL-1Ra Placebo Placebo

13. McIlwraith, Frisbie Placebo IL-1Ra Frisbie, D.D., et al., Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther, 2002. 9(1): p. 12-20.

14. Pain reduction in arthrosis Gelenk - Studie Uni-Düsseldorf (05 / 2005) VAS score of pain in the Orthokin® patients(n=143)was lower for 31% more than in the patients with therapy ofHialuronyc acid.- (n=138) and in Placebo-group (n=118). p<0,001* P>0,05** * p<0,001 za usporedbu Orthokin® vs. HA i P ® Hya-Ject® NaCl ** p> 0,05 za usporeduHA vs. P VAS Scores (%) reduction after 26 weeks

15. Orthokin® - physical stimulation of body imunoproteins Production process

16. Production process of the autologic conditioned serum – ORTHOKIN

17. Indication for Orthokin®therapy Acute and chronic joint diseases of musculosceletal system: gonarthrosis, coxarthrosis, shoulder arthrosis, as chondral trauma demages, lumboischialgy, traumatic muscular and tendon ruptures, etc.

18. Orthokin® – therapy :joints Orthokin®- directly intraarticulary Dose: 1 injections 2 ccm per week for 5 weeks

19. Orthokin® - Terapija:Lumboishialgy Orthokin®- directly on the radicular Dose: 1 injections 2 ccm per week for 3 weeks

20. For informations about Orthokin therapy please contanct : ALFA - ARTHRO d.o.o. Športska 26 Varaždin www.alfa-arthro.hr